Latest Breaking News On - Associate attending physician - Page 1 : comparemela.com

SELLAS Life Sciences Presents Positive Key Immunobiological

Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14.

South koreaMemorial sloan kettering cancer centerNew yorkUnited statesSoult ukpyolsiBruce mackleDragan cicicRoisine ocearbhaillCellular therapy serviceGynecologic medical oncology serviceMerck sharp dohmeClinical developmentGenfleet therapeutics shanghai incInternational gynecologic cancer society annual global meetingLifesci advisorsPhysician at memorial sloan kettering cancer center

SELLAS Life Sciences (SLS) announces positive Phase 1/2 data from galinpepimut-S in combination with Keytruda

SELLAS Life Sciences (SLS) announces positive Phase 1/2 data from galinpepimut-S in combination with Keytruda
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesNew yorkSoult ukpyolsiDragan cicicRoisine ocearbhaillClinical developmentCellular therapy serviceSellas life sciences group incGynecologic medical oncology servicePhysician at memorial sloan kettering cancer centerInternational gynecologic cancer society annual global meetingMerck co incSciences groupResearch directorClinical director

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three.

United statesUnited kingdomMario corsoHelena yuJulie seidelSergey yurasovDiamond therapeutics incInternational conference on molecularMemorial sloan kettering cancer centerExchange commissionCompany masterkeyGlobenewswire incDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitor

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMario corsoJulie seidelHelena yuSergey yurasovCompany masterkeyInternational conference on molecularPhysician at memorial sloan kettering cancer centerDiamond therapeutics incExchange commissionDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitorNon small cell lung cancer

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJulie seidelSergey yurasovMario corsoHelena yuExchange commissionPhysician at memorial sloan kettering cancer centerCompany masterkeyDiamond therapeutics incInternational conference on molecularDiamond therapeuticsMolecular targetsCancer therapeuticsGeneration inhibitorNon small cell lung cancer